Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brilacidin - Alfasigma/Innovation Pharmaceuticals

Drug Profile

Brilacidin - Alfasigma/Innovation Pharmaceuticals

Alternative Names: Brilacidin tetrahydrochloride; Brilacidin-Ocular; Brilacidin-OM; Brilacidin-Otic; Defensin-mimetic - Innovation Pharmaceuticals; HDP-mimic - Innovation Pharmaceuticals; Host defense protein-mimic - Innovation Pharmaceuticals; PMX-30063

Latest Information Update: 26 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PolyMedix
  • Developer Innovation Pharmaceuticals
  • Class Amides; Anti-infectives; Anti-inflammatories; Antiacnes; Antibacterials; Antivirals; Foot disorder therapies; Guanidines; Peptidomimetics; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Immunomodulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Phase II COVID 2019 infections; Skin and soft tissue infections; Stomatitis; Ulcerative proctitis
  • Preclinical Alphavirus infections; Bunyavirus infections; Coronavirus infections; Ebola virus infections; Marburg virus disease; Nipah virus infections; West Nile virus infections; Zika virus infection
  • No development reported Acne; Atopic dermatitis; Diabetic foot ulcer; Hidradenitis suppurativa; Inflammatory bowel diseases; Otitis; Wounds
  • Discontinued Intestinal infections; Ophthalmic infections; Ulcerative colitis

Most Recent Events

  • 21 Jun 2023 Innovation Pharmaceuticals has patents pending for Brilacidin in fungal diseases in USA
  • 21 Jun 2023 Innovation Pharmaceuticals receives notice of allowance for patent covering arylamide compounds for treatment of viral infections in USA
  • 06 Jun 2023 Innovation Pharmaceuticals has patent protection for Brilacidin in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top